Get started
Novavax Inc (Extended Hours)Novavax Inc (Extended Hours)Novavax Inc (Extended Hours)

Novavax Inc (Extended Hours)

No trades
See on Supercharts
Overview News
Ideas
Discussions Seasonals

NVAX trade ideas

$NVAX getting ready for break out Price has been respecting the daily uptrend on this pennant pattern formed on the daily time frame. The pattern its formed suggest a break out will likely follow. With the president trying to get everyone vaccinated as soon as possible im bullish on the catalyst. The daily RSI is in a neutral position, and the stochastic looks to be shifting towards the upside. On the 4hr and 1 hr the stochastic are showing bullish potential with no crosses in the moving averages. I charted this on the daily so ill be looking to buy at least 30 days out. Not much more to say here other than buy the dip. lmk what y'all think about the TA
NASDAQ:NVAXLong
by don_shula
4
Trading Novavax after BreakoutNVAX jumped roughly 20% overnight after announcing 96.4% efficacy against the disease caused by the original COVID-19 strain. This single move caused the shares to break out from the downside channel and crack through the 50-day and 20-day moving averages. With this important resistance zone left behind, the shares are poised to open just above the yearly Fibonacci R2 and monthly S1 levels ($216 and $213; RY2 and SM1 lines on the chart). The question is whether the bulls can push the stock even higher today. Personally, I do not rule out that such a powerful upside gap - amid broader market concerns - could trigger some profit taking. Therefore, I will be watching to see if the stock can hold the RY2 / SM1 zone. If this happens, we can see NVAX approaching the $250 zone followed by the monthly pivot level ($258, PM) near-term. On the downside , a break below RY2 / SM1 will put the 20- and 50-day moving averages to the test. An even more bearish scenario involves retesting recent diagonal resistance and potential gap filling at $188. This zone, however, should serve as very strong support, where we will definitely see buybacks.
NASDAQ:NVAX
by tbiktag
Comparison chart $OCGN with $NVAX Tribune News Service New Delhi, March 10 India’s indigenous COVID-19 vaccine COVAXIN is no longer to be used in clinical trial mode and has got the nod of national experts to be used under the normal restricted emergency use authorisation route, just like the Serum Institute manufactured Covishield. The move entails a huge boost to the indigenous Covid vaccine sector and the ICMR and Bharat Biotech, the joint developers of COVAXIN. The restricted emergency use authorisation to COVAXIN had been held up in early January as the vaccine’s phase 3 efficacy data was unavailable till then and its efficiency was yet to be established though the vaccine was safe and immunogenic in early phase 1 and 2 trials. The drug regulator had at that time approved the use of COVAXIN in clinical trial mode until efficacy data came. With Bharat Biotech presenting interim phase 3 data showing 81 per cent efficacy for COVAXIN and Lancet also declaring the vaccine safe and immunogenic with minimum side effects based on phase 2 trial data published yesterday, the subject experts at the Central Drug Standard Control Organisation today reviewed COVAXIN data for two hours and recommended that the vaccine be brought out of the use in clinical trial mode and placed in the category of restricted emergency use. This means beneficiaries of COVAXIN would not need to be followed up closely after administration of the jab, something that was mandatory when the vaccine was permitted for use in clinical trial mode. COVAXIN export will also get a boost with the move.
NASDAQ:NVAXLong
by BADQOMOCAWGOWLD
1
My lucky 14x profit on NVAX and why I am still ready to short itI covered my shorts on NVX once 150 was reached. See my linked idea. I did this trade with puts. Which were mostly crazy expensive at the time, but I was able to get 175 3/05 Puts for about $1.50 a couple of weeks ago. I sold them today for an average price of 20.5, which gives this trade a 14x result. Looking at the chart and at fundamentals, I will be looking for a short reentry. Let's see if I get a chance! There seems to be good support at 70-80 level.
NASDAQ:NVAXShort
by roman63rus